Experienced scientists at Creative Biolabs are glad to apply our special expertise to help our worldwide customers in the development of custom delivery systems (including lipid-based vectors, polymer-based vectors, hybrid vectors and enveloped virus-like particle) for mRNA.
mRNA has several advantages over DNA for gene transfer and expression, including the lack of any requirement for nuclear localization or transcription and the nearly negligible possibility of genomic integration of the delivered sequence. After over two decades of development, mRNA has shown broad potential as a therapeutic. The design and chemistries used to synthesize mRNAs have advanced to a point where they enable adequate stability and immune evasion, while at the same time allowing the maintenance of efficacy and specificity. Current clinical efforts are focused on vaccination, protein replacement therapies, and treatment of genetic diseases. The clinical translation of mRNA therapeutics has been made possible through advances in the design of mRNA manufacturing and intracellular delivery methods.
A desired mRNA delivery vehicle must include: 1) protection of mRNA from extra-cellular nuclease digestion; 2) cell-specific uptake; 3) endosomal escape; 4) the desired level of delivery vehicle-specific immunostimulatory properties; 5) efficient clearance of delivery vehicle components; 6) low toxicity. Although aided by high-throughput screening technologies, the delivery technologies have greatly progressed by the discovery of potent and bio-compatible materials, broad application of mRNA is still limited by the need for improved delivery systems.
mRNA is emerging as a highly versatile biological construct for the creation of impactful medicines. mRNA therapeutics directed toward infectious disease and cancer are in clinical development with encouraging early reads on tolerability and efficacy. The versatility of mRNA has created several distinctive opportunities for clinical application, each with distinctive delivery requirements.
Integrating cutting-edge platforms as well as substantial experience in the study of delivery vehicles for mRNA, Creative Biolabs is pleased to address the scientific and technical challenges in the development of custom delivery vehicles for mRNA. Our commonly used delivery vehicles for mRNA include but are not limited to:
Lipids and lipid-like materials represent the second major class of nanoparticle-based delivery vehicles for RNA. Cationic lipids are often used to electrostatically bind the nucleic acid while ionizable lipids are positively charged only in acidic environments, and this ionizable behavior is thought to enhance efficacy through helping with endosomal escape and reducing toxicity. Our scientists have accumulated rich experience in enhancing the stability and efficacy of lipid-based mRNA delivery systems. We are confident in providing clients with the best services at the most competitive cost.
Nanoparticle encapsulation physically protects mRNA from degradation and, depending on the specific chemistry, can aid in cellular uptake and endosomal escape. Given their high degree of chemical flexibility, polymers are commonly used materials for nanoparticle-based delivery. Creative Biolabs gathers lots of scientists who are proficient in the development of polymer-based mRNA delivery systems, mainly including polyplex and micelleplex.
The hybrid delivery system has shown promising results for the delivery of mRNA, with the mRNA encapsulated in a hybrid nanoparticle composed of a lipid-like material with a polymeric PLGA core. The hybrid formulation is thermodynamically favorable, with respect to hydrophobic, van der Waal, and electrostatic interactions. Creative Biolabs is pleased to share our cutting-edge technology and extensive expertise in the development of hybrid mRNA delivery systems to facilitate our clients' research and project development.
Enveloped Virus-Like Particles (eVLPs) are advanced delivery systems that mimic natural viruses but are non-infectious. They are composed of viral structural proteins and host membrane components, enhancing their stability, immunogenicity, and delivery efficiency. eVLPs are used for various applications, including vaccine delivery, gene therapy, and cancer treatment. They can efficiently encapsulate and deliver mRNA to target cells, improving therapeutic outcomes. Creative Biolabs offers custom eVLPs for research purposes, tailored to specific needs in protein, tRNA, rRNA, and mRNA delivery.
A: Creative Biolabs boasts an extensive library of mRNA delivery vectors, including but not limited to various lipid carriers, polymer-based vectors, hybrid vectors, and enveloped virus-like particles. Over ten different delivery vectors are available for our clients to choose from.
A: Effective mRNA delivery ensures protection from extracellular nucleases, cell-specific uptake, endosomal escape, and minimal toxicity.
A: Our system is highly stable, efficient and competitively priced, and provides tailored services to meet specific research needs.
A: Yes, we can provide solutions tailored to your experimental needs to address specific scientific and technical challenges in mRNA delivery.
A: We provide comprehensive mRNA delivery vehicle support, including project consulting, design and development, optimization and post-delivery assistance to ensure successful results.
This article explores how the tail length of ionizable lipids (ILs) in lipid nanoparticles (LNPs) affects the delivery efficiency of mRNA. The study synthesizes a library of ILs with different tail lengths and tests their efficacy in delivering three types of mRNA: firefly luciferase (FLuc), erythropoietin (EPO), and Cas9. The results show that shorter IL tails are more effective for larger mRNAs like Cas9, while longer tails work better for smaller mRNAs like EPO. The C10-200 IL significantly enhanced liver delivery of FLuc mRNA, indicating the importance of optimizing IL tail length for different mRNA sizes to improve LNP-mediated mRNA delivery. Creative Biolabs offers a wide range of delivery vector libraries to choose from. Our experienced scientists can provide clients with the best mRNA delivery vector design and synthesis solutions.
Fig.1 Characterization of each lipid delivery system.1
Reference
